The mission of the Centre for Systems Medicine is to provide a translational research centre which identifies genes, proteins and metabolites implicated in human disease. The Centre utilizes bioinformatics, systems biology and machine learning approaches to develop new prognostic tools for the treatment of cancer, neurological and metabolic disorders and  to develop more targeted therapies for patients.

What is Systems Medicine?

For a short and understandable explanation please watch the animation provided by ZonMw

CSM Director, Prof. Jochen Prehn provides and overview of the research activities at the Centre for Systems Medicine

For additional Videos, click on each investigator’s page to learn about what projects they are leading at the CSM                                             

CSM Director: Prof. Jochen Prehn


 CSM Scientific Liaison Officer: Dr. Helena Bonner  


Recent Highlights:

Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma (2024)

Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy (2023)

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers (2023)

Multiplexed Immunofluorescence Imaging Reveals an Immune Rich Tumor Microenvironment in Mucinous Rectal Cancer Characterized by Increased Lymphocyte Infiltration and Enhanced PD-1 Expression


An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution

Mechanisms and mathematical modelling of ROS production by the mitochondrial electron transport chain

Archive of "Gut". - PMC

Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC)

Archive of "Acta Pharmacologica Sinica". - PMC
Angiogenin and tRNA fragments in Parkinson’s disease and neurodegeneration.

System-based approaches as prognostic tools for glioblastoma 

CDD Editor's Pick : Cell Death & Differentiation

An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution

Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform


Cover image

Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer’s disease neurons.  Aging Cell. 2019 Jun 

Journal of Clinical Oncology

 A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.  JCO Clin Cancer Inform. 2019 

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat Commun. 2018 Oct  

Click here for a list of all the Publications